Loqtorzi Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing npc diagnosis rates in endemic regions, advancements in immunotherapy research, early success of pd-1 blockade trials, growth of oncology research funding, expansion of specialty cancer centers.

The growth in the forecast period can be attributed to increasing global approvals for immunotherapy drugs, rising investment in rare cancer treatments, expansion of oncology biologics access, growing use of combination immunotherapies, continued innovation in immune modulation therapies. Major trends in the forecast period include increasing adoption of pd-1 inhibitors in rare cancers, growing focus on nasopharyngeal carcinoma treatment, expansion of immuno-oncology pipelines, rising use of immune checkpoint blockade therapies, enhanced global clinical trial activity.

The increasing prevalence of nasopharyngeal carcinoma is expected to drive the growth of the Loqtorzi market in the coming years. Nasopharyngeal carcinoma is a type of cancer that affects the nasopharynx and is closely associated with Epstein-Barr virus infection, with early diagnosis playing a crucial role in treatment success. The growing prevalence of nasopharyngeal carcinoma can be attributed to factors such as greater exposure to the Epstein-Barr virus, genetic predisposition, environmental influences like tobacco and alcohol use, and dietary habits, particularly the consumption of salted and preserved foods. Loqtorzi (toripalimab) aids patients with nasopharyngeal carcinoma (NPC) by enhancing the immune system’s ability to target cancer cells through the inhibition of the PD-1 pathway, offering a novel treatment option for those with recurrent or metastatic NPC, either in combination with chemotherapy or as a monotherapy after disease progression. For example, in October 2024, Cancer Research UK, a UK-based registered charity, reported that the incidence of head and neck cancers in the UK is projected to increase by 3% when comparing the periods 2023-2025 with 2038-2040. Therefore, the rise in the prevalence of nasopharyngeal carcinoma is contributing to the growth of the Loqtorzi market.

A key trend in the Loqtorzi market is the focus on developing biosimilars to expand its portfolio and offer more affordable alternatives to biologic therapies. Biosimilars are biologic products that closely resemble an approved reference product, with no significant differences in safety or effectiveness. They provide a cost-effective alternative to expensive biologic drugs once the original product's patent expires. For instance, in November 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, introduced a biosimilar of Coherus BioSciences' Loqtorzi (toripalimab) in India under the brand name Zytorvi. The drug is indicated for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare cancer. Loqtorzi was FDA-approved in October 2023 for first-line treatment of RM-NPC in combination with cisplatin and gemcitabine, as well as a monotherapy for patients with disease progression after platinum-based chemotherapy. It is the only FDA-approved immuno-oncology drug for this indication.

In January 2024, Inovio Pharmaceuticals Inc., a US-based biotechnology company, entered into a partnership with Coherus BioSciences Inc. Through this partnership, Inovio aims to advance the development of INO-3112 in combination with Loqtorzi (toripalimab-tpzi). This collaboration is focused on treating patients with locoregionally advanced, high-risk, HPV16/18-positive oropharyngeal squamous cell carcinoma (OPSCC), a common form of throat cancer. The partnership seeks to combine the unique mechanisms of both therapies to enhance clinical outcomes for patients with this type of throat cancer. Coherus BioSciences Inc., a US-based biotech company, is the developer of Loqtorzi.

Major companies operating in the loqtorzi market are Coherus BioSciences Inc., Shanghai Junshi Biosciences Co. Ltd.

North America was the largest region in the loqtorzi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the loqtorzi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the loqtorzi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the loqtorzi market by increasing costs of imported biologic raw materials, clinical trial supplies, monoclonal antibody production equipment, and specialized cold-chain logistics. Asia-Pacific and Europe are most affected due to reliance on cross-border manufacturing and clinical research networks, while North America faces higher biologics equipment costs. These tariffs are increasing overall treatment development and commercialization expenses. However, they are also supporting domestic biologics manufacturing, regional clinical trial infrastructure, and localized production strategies for oncology immunotherapies.

The loqtorzi market research report is one of a series of new reports that provides loqtorzi market statistics, including loqtorzi industry global market size, regional shares, competitors with a loqtorzi market share, detailed loqtorzi market segments, market trends and opportunities, and any further data you may need to thrive in the loqtorzi industry. This loqtorzi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Loqtorzi (toripalimab-tpzi) is a PD-1 inhibitor biologic drug primarily used in the treatment of nasopharyngeal carcinoma (NPC), particularly in metastatic or recurrent cases. By blocking the PD-1 receptor on T-cells, Loqtorzi enhances the immune system's ability to target and destroy cancer cells.

The main formulations in the Loqtorzi market include an injectable intravenous formulation and lyophilized powder for reconstitution. The injectable formulation refers to the intravenous (IV) version of toripalimab, a monoclonal antibody primarily used in the treatment of cancers like small cell lung cancer (SCLC) and nasopharyngeal carcinoma. Loqtorzi is indicated for the treatment of SCLC and other solid tumors. The patient population for Loqtorzi includes adults, geriatric patients, and pediatric patients. Distribution of the drug occurs through various channels, including direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies. End users include hospitals, oncology clinics, specialty pharmacies, and research institutions.

The loqtorzi market consists of sales of diagnostic kits, biomarker assays, companion diagnostics, Loqtorzi-related drug delivery systems, and post-treatment care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.